Protein nanometer particle for wrapping slightly soluble medicines and preparation method thereof

Abstract

The invention belongs to the field of pharmacy and discloses a protein nanometer particle for wrapping slightly soluble medicines and a preparation method thereof. The formula of the particle comprises, by weight, 0.1% to 10% of slightly soluble medicines, 0.1% to 40% of soluble carrier material and 50% to 90% of protein material. The preparation method comprises the steps of first making the slightly soluble medicines and the soluble carrier material into a soluble carrier solid dispersoid containing the slightly soluble medicines; then adding the obtained solid dispersoid into an aqueous medium containing the protein material, mixing evenly, performing high shearing condition processing to mixture, and obtaining suspension of the protein nanometer particle containing the slightly soluble medicines; and further preparing a required dosage form. The protein nanometer particle has the advantages of being high in medicine loading quantity, even in grain diameter, good in stability, high in safety and the like. The preparation method avoids residue of toxic organic solvents, improves safety of clinical medicine usage, and is easy in process, low in cost and strong in operability.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a protein nanoparticle encapsulating insoluble drugs and a preparation method thereof. Background technique [0002] The poorly soluble drugs involved in the present invention are taxane drugs as examples. Taxane drugs (such as paclitaxel, docetaxel, etc.) are one of the most effective anti-tumor drugs currently used clinically. Paclitaxel is a natural product isolated from the bark or needles of Taxus or its species discovered in the 1970s. Docetaxel is a semi-synthetic product, which was later discovered to be a class of anti-tumor agents with a special anti-tumor mechanism of action . [0003] The anti-tumor mechanism of taxane drugs is to promote microtubule polymerization and reduce the depolymerization speed of microtubules, so that the microtubules are in a stable non-functional state, thereby achieving the purpose of preventing tumor cell mitosis and proliferation. And preclinica...

AI Technical Summary

Problems solved by technology

[0015] However, through the direct chemical coupling of HSA and drugs, there are the following problems: 1) The range of drug selection is narrow: the drug needs to have a certain reactive group, and the drug is prone to failure during the chemical coupling process; 2) The curative effect is uncertain Performance: The ease of breaking the chemical bond between the drug and HSA determines the efficacy of the drug. If it breaks too fast, HSA will lose its advantage as a carrier material. If it breaks too slowly, the drug will not be able to exert its curative effect; 3) High cost and low drug loading : In the coupling process, the drug dosage is much larger than HSA, and the coupling drug amount is limited, resulting in high preparation costs (especially the high price of anti-tumor drug raw materials) and low drug loading in the system.

Because HSA is highly water-soluble, the prepared nanoparticles need to be cured, that is, add a chemical cross-linking agent to cross-link albumin or heat to denature the protein. The former is more toxic, and it is easy for the drug to cross-link at the same time and lose its efficacy , the latter is not suitable for the loading of temperature-sensitive drugs; in addition, some people think that the method of cross-linking or heat curing will reduce the hydrophilicity of the surface of HSA nanoparticles, thereby reducing the circulation time in the blood, which is not conducive to tumor targeting;

[0020] 3) The post-processing process is complex

Due to the use of toxic additives such as surfactants, oils, and chemical cross-linking agents in the process, a large amount of organic solvents are required to clean and purify, but a small amount of residue will still bring hidden dangers to drug safety; high-speed centrifugation (16000-20000g) is used to collect nano Particles, not only have high requirements for instruments, but also have poor redispersibility in water;

[0021] 4) The scope of applicable drugs is small

But the precipitation of nanoparticle occurs very soon, it is more difficult when carrying out described microporous membrane filtration (1.2um, 0.8um, 0.45um and 0.22um), and the situation of clogging occurs easily in filter membrane, and its freeze-dried product is in The nanosuspension formed after reconstitution in physiological solution is unstable, with macroscopic precipitation appearing within about 8 hours, which is completely different from the results claimed in the patent that the stability is greater than 24 hours

Images